



SolAeroMed Inc.
Unit 2, Research Transition Facility
3535 Research Road N.W.
Calgary, AB, T2L 2K8

Email: info@solaeromed.com

SolAeroMed Shareholder Newsletter #12 March 20 2015

Hello SAMi shareholders

We write to provide an update on our evolving development at SolAeroMed (SAMi) and to invite you to a SolAeroMed social event.


April 8, from 5pm - 10pm
300, 1025-10th St SE T2G 3E1 (top 2 floors of brick building, off 9th Ave in Inglewood)

This is a kick off social event preceding closed 2-day SolAeroMed management and board discussion of SolAeroMed's business and clinical development plans. SolAeroMed board and management will all be present on April 8th (jet lag allowing !) and look forward to informed discussion on our progress and answering any questions you may have. We also expect our local collaborators to attend, including clinical teams, consultants, and firms we have been working with in progressing our business and clinical development. We plan no formal presentations. We will put on food & drink refreshments (beer/wine, soft-drinks) and live music. Please join us if you have the time and are in the area.

You may wish to visit www.solaeromed.com as we've revised the content to provide a more investor and business focus, and we are exploring the value of alternative www formats.

Our clinical trial of S1226 continues to progress well under the guidance of Prof Richard Leigh. This 'proof of concept' trial is designed to demonstrate both safety and efficacy in asthmatics. We expect completion in Q2/3 this year and will be sharing results when they are officially decoded and reportable.

We have recently filed our 4th SolAeroMed patent application. This surrounds the realization that low levels of CO₂ can effectively treat sleep apnea, as part of Prof Green's background R&D in the rat model on S1226. We combined this realization with Displacement Ventilation engineering knowledge from John Dennis and came up with a new device to deliver gases and vapours to treat sleep apnea – early days yet, but this offers the benefit of people with sleep apnea avoiding wearing the cumbersome and invasive CPAP masks. Now that we have put patent protection on this device invention, we are exploring partnerships and development options.



SolAeroMed has progressively become a more and more complex biotech company. While we continue to focus on S1226 as our leading drug technology, we also work to progress S1229 drug development to treat Acute Respiratory Distress Syndrome (ARDS), and we now have patents and development around 2 new

medical devices – one to deliver S1226 and the other to treat sleep apnea. Our upcoming April meeting with management and board will review the potential in each of these areas, and debate how to best focus SolAeroMed resources.

SolAeroMed looks forward to further evolution and value add as we progress developments. We will continue to provide updates through www.solaeromed.com and these occasional newsletters. On behalf of SolAeroMed management and board, I hope you can join us for our April 8th social event !

Sincerely

John Dennis, PhD CEO, SolAeroMed
+1 403 689 5989 jdennis@solaeromed.com